Results 141 to 150 of about 2,022,996 (246)

Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

<p>Primary tumor challenge with NeoAg #5 knocked out CT26 tumor cells. Mice were immunized with CD8#5 mono-epitope vaccine and after 14 days, mice were s.c. inoculated with CT26 cells or CT26 #5KO cells, resulting in 50% and 0% of tumor free mice, respectively. Bars show the percentage (%) of tumor free (grey) and tumor bearing (black) mice (n=8).
Anna Morena D'Alise, Elisa Scarselli, Valeria Poli, Massimo Mallardo, Carmen Caiazza, Laura Conti, Giuseppina Romano, Simona Allocca, Gabriella Cotugno, Laura Antonucci, Laura Seclì, Guido Leoni, Fulvia Troise, Lidia Avalle, Linda Nocchi, Irene Garzia   +15 more
openaire   +1 more source

Teleport‐stabilised quantum‐walk transport for robust neoantigen ranking in near‐tie regimes: A reproducible colorectal benchmark

Clinical and Translational Discovery, Volume 6, Issue 6, December 2026.
Teleport‐stabilised quantum‐walk transport for robust neoantigen ranking in near‐tie regimes. The analysis proceeds from patient‐conditioned candidate definition to weighted evidence‐graph construction, quotient‐basin compression, continuous‐time quantum‐walk (CTQW)/discrete‐time quantum walk (DTQW) transport, teleport‐consensus stabilisation, ABHA ...
Ioannis Grigoriadis
wiley   +1 more source

Supplementary Table 1 from SpliceMutr Enables Pan-Cancer Analysis of Splicing-Derived Neoantigen Burden in Tumors

<p>Supplementary Table S1. TCGA cancer study abbreviations and names.</p>
Ludmila Danilova, Elana J. Fertig, Daria A. Gaykalova, Rachel Karchin, Valsamo Anagnostou, Alexander V. Favorov, Elizabeth M. Jaffee, Nilofer S. Azad, Jessica Gore, Ali M. Saeed, Tamara Y. Lopez-Vidal, Neeha Zaidi, Mark Yarchoan, Archana Balan, Xiaoshan M. Shao, Michael D. Kessler, Theron Palmer   +16 more
openaire   +1 more source

TAMAVAQ/Q‐TAMAVAQ: Fubini–study CTQW graph transport and constrained margin‐based ranking for neoantigen candidate prioritization in lower‐grade glioma and glioblastoma

Clinical and Translational Discovery, Volume 6, Issue 6, December 2026.
Abstract Background Personalized neoantigen vaccine design for glioma requires the integration of mutation‐derived peptide evidence, molecular properties, HLA coverage and finite manufacturing capacity. TAMAVAQ/Q‐TAMAVAQ combines quantum‐geometric descriptor representation with graph transport and auditable peptide‐panel assembly.
Ioannis Grigoriadis
wiley   +1 more source

Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

<p>Mutation loss in developed CT26 tumors after GAd CD8#5 and CD8#23 vaccine. A) Mice were immunized with mono-epitope GAd CD8#5 or B) CD8#23 vaccines and 14 days later, mice were inoculated s.c. with 2x10^5 CT26 cells. Mutation relative to nAg#5 (A) and nAg#23 (B) was checked by DNA sequencing in developed tumors.
Anna Morena D'Alise, Elisa Scarselli, Valeria Poli, Massimo Mallardo, Carmen Caiazza, Laura Conti, Giuseppina Romano, Simona Allocca, Gabriella Cotugno, Laura Antonucci, Laura Seclì, Guido Leoni, Fulvia Troise, Lidia Avalle, Linda Nocchi, Irene Garzia   +15 more
openaire   +1 more source

Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.

, 2016
Due to advances in sequencing technology, somatically mutated cancer antigens, or neoantigens, are now readily identifiable and have become compelling targets for immunotherapy.
Spencer D Martin, Darin A Wick, Brad H Nelson, David R. Kroeger (470607), Brad H. Nelson (204518), Julie S. Nielsen (24467), Kwame Twumasi-Boateng (171499), Robert A. Holt (222944), Kwame Twumasi-Boateng, Julie S Nielsen, Spencer D. Martin (2793634), David R Kroeger, Darin A. Wick (234609), Robert A Holt, Scott D Brown, Scott D. Brown (303896), Twumasi-Boateng Kwame, Nielsen Julie S., Holt Robert A., Brown Scott D., Kroeger David R., Nelson Brad H., Martin Spencer D., Wick Darin A.   +23 more
core   +1 more source

The molecular pathological basis and potential clinical applications of ‘zero‐budding’ status in stage II colorectal cancer

The Journal of Pathology: Clinical Research, Volume 12, Issue 6, November 2026.
Abstract In the personalized management of stage II colorectal cancer (CRC), traditional TNM (Tumor, Node, Metastasis) staging has limited ability to accurately stratify the risk of postoperative recurrence. Consequently, oncologists frequently face a major therapeutic dilemma when determining the use of adjuvant chemotherapy in these patients ...
Ying‐nan Liu, Ben Wang, Qian Xu
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations

Cancer Immunology, Immunotherapy
Pediatric solid tumors remain among the most treatment-refractory childhood malignancies, defined by biological features that have largely resisted the immunotherapeutic advances transforming adult oncology.
Mahsa Fatahichegeni, Mohammad Amin Ansarian, Mi Xiao, Wenjuan Gao, Ruiming Shi   +4 more
doaj   +1 more source

Photoacoustic Nanotagging for In Vivo Tracking and Optimization of Macrophage Immunotherapy in Solid Tumors

Advanced Materials, Volume 38, Issue 61, 2 November 2026.
Macrophage‐based immunotherapy for solid tumors is limited by poor tracking of cell localization and persistence. This study introduces nanotagged macrophages enabling near‐infrared photoacoustic imaging for real‐time monitoring. IFNγ‐conjugated tags enhance antitumor polarization without harming viability.
Seoyoon Song, Melissa Cadena, Myeongsoo Kim, Euisuk Chung, Jeungyoon Lee, Zlata Brushevich, Seonghun Shin, Paul S. Pelkowski, Stanislav Y. Emelianov   +8 more
wiley   +1 more source